{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:05:48Z","timestamp":1747159548022,"version":"3.40.5"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejim.2024.07.036","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T05:30:00Z","timestamp":1722490200000},"page":"171-173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical trial landscape for immune thrombocytopenia: Progress and the long road ahead"],"prefix":"10.1016","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4837-7515","authenticated-orcid":false,"given":"Hui","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shufen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengshan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.ejim.2024.07.036_bib0001","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","article-title":"A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia","volume":"390","author":"Chen","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2024.07.036_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(24)00139-X","article-title":"Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study","author":"Hu","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.ejim.2024.07.036_bib0003","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-024-01793-5","article-title":"Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejim.2024.07.036_bib0004","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024025067","article-title":"Eltrombopag plus diacerein vs. eltrombopag in patients with ITP: a multicenter, randomized, open-label, phase 2 trial","author":"Sun","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejim.2024.07.036_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-023-01401-z","article-title":"How we treat primary immune thrombocytopenia in adults","volume":"16","author":"Liu","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"10426","key":"10.1016\/j.ejim.2024.07.036_bib0006","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0140-6736(23)01952-9","article-title":"A new age of precision gene therapy","volume":"403","author":"Schambach","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejim.2024.07.036_bib0007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00281-021-00887-4","article-title":"Functional interrogation of autoimmune disease genetics using CRISPR\/Cas9 technologies and massively parallel reporter assays","volume":"44","author":"Ding","year":"2022","journal-title":"Semin Immunopathol"},{"issue":"7926","key":"10.1016\/j.ejim.2024.07.036_bib0008","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","article-title":"Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ejim.2024.07.036_bib0009","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"Muller","year":"2024","journal-title":"N Engl J Med"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524003339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620524003339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T13:09:26Z","timestamp":1733144966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620524003339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":9,"alternative-id":["S0953620524003339"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2024.07.036","relation":{},"ISSN":["0953-6205"],"issn-type":[{"type":"print","value":"0953-6205"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trial landscape for immune thrombocytopenia: Progress and the long road ahead","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2024.07.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Federation of Internal Medicine. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}